OpGen (NASDAQ:OPGN) Share Price Crosses Below Fifty Day Moving Average of $0.50

Shares of OpGen, Inc. (NASDAQ:OPGNGet Rating) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.50 and traded as low as $0.41. OpGen shares last traded at $0.42, with a volume of 120,439 shares.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OPGN. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OpGen in a report on Friday, June 10th. Alliance Global Partners downgraded OpGen to a “neutral” rating in a report on Tuesday, July 19th. Finally, StockNews.com started coverage on OpGen in a report on Thursday. They issued a “sell” rating for the company.

OpGen Trading Down 6.8 %

The stock has a market capitalization of $18.71 million, a price-to-earnings ratio of -0.48 and a beta of -0.37. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.32 and a current ratio of 1.40. The firm has a fifty day moving average of $0.50 and a 200-day moving average of $0.57.

OpGen (NASDAQ:OPGNGet Rating) last announced its quarterly earnings results on Thursday, August 11th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. OpGen had a negative return on equity of 75.61% and a negative net margin of 624.26%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.00 million. As a group, equities analysts predict that OpGen, Inc. will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. GSA Capital Partners LLP acquired a new stake in OpGen, Inc. (NASDAQ:OPGNGet Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 97,810 shares of the medical research company’s stock, valued at approximately $73,000. GSA Capital Partners LLP owned about 0.21% of OpGen at the end of the most recent reporting period. 7.24% of the stock is owned by hedge funds and other institutional investors.

About OpGen

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.